Clinical trial
VaxTeen Hepatitis B Vaccine Booster Study
NCT00144313 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00144313 |
|---|---|
| Title | VaxTeen Hepatitis B Vaccine Booster Study |
| Official title | Persistence of Antibody and Response to Booster of a Recombinant Hepatitis B Vaccine in Children Who Responded to a Primary Course of 2.5µg Recombinant Hepatitis B Vaccine as Infants |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | Alaska Native Medical Center |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis |
| Intervention type | Biological |
| Interventions | hepatitis B vaccine |
| Enrollment | 60 |
| Start date | Aug 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Sep 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: